Sarah Lee

CMC Leadership in Cell & Gene Therapies

Role: Executive Director, Head of Cmc Portfolio Management at Sana Biotechnology, Inc.
Location: Seattle, WA, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About Sarah Lee

An immunologist and a strategic technical leader specialized in overseeing CMC activities of cell & gene therapy products for both early and late stage programs. Highly developed interpersonal, project management, and communication skills with focus on building diverse and resilient teams.

Experience

Executive Director, Head of Cmc Portfolio Management
Sana Biotechnology, Inc.
Mar 2023 — Present
Establish phase-appropriate CMC strategy and business processes to drive successful completion of program deliverables.

Education

University of Washington
Doctor of Philosophy (Ph.D.), Immunology
University of California, Berkeley
Bachelor of Arts (B.A.), Molecular and Cell Biology, Immunology

Skills

Project Management
Life Sciences
Biotechnology
Protein Purification
Pcr
Molecular Biology
Process Simulation
Purification
Immunoassays
Elisa
Manufacturing Science
Pharmaceutical Industry
Monoclonal Antibodies
Immunology
Flow Cytometry
In Vivo
Process Development
Pharmacology
Cell Culture
In Vivo Models
Antibodies

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@sana.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Sana Biotechnology, Inc.

Biotechnology Research · 255 employees · Founded 2018 · Seattle, Washington, United States

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

sana.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Sarah Lee

Experience

Executive Director, Head of Cmc Portfolio Management

Education

University of Washington

University of California, Berkeley

Skills

Find verified contacts for anyone on LinkedIn